{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:23:09Z","timestamp":1759040589738},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T00:00:00Z","timestamp":1261440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open\u2010label olanzapine monotherapy (mean modal dose, 15\u2009mg\/day) for 8 weeks. Assessments of psychopathology (Montgomery\u2013Asberg Depression Rating Scale [MADRS], Quick Inventory of Depressive Symptomatology [QIDS\u2010SR\u201016], Young Mania Rating Scale [YMRS]), clinical global state (Clinical Global Impressions [CGI] scale), and safety\/tolerability were performed at baseline, and at 1, 2, 4, 6, and 8 weeks. Seventeen patients (85.0%) completed the study. Improvement in MADRS total scores was observed after the first week of treatment, and at all remaining follow\u2010up time points (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.005). Parallel improvement in QIDS\u2010SR\u201016 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and CGI\u2010Severity (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) was observed between baseline and study endpoint. Nine (45%) subjects achieved positive treatment response, eight of whom (40%) also achieved symptom remission. There were significant increases in weight (+3.2\u2009kg, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and body mass index (+1.1\u2009kg\/m<jats:sup>2<\/jats:sup>, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), but not fasting glucose or lipids, with the exception of reduced triglyceride levels in the overall sample, and reduced HDL cholesterol in females. Olanzapine may be an effective, well\u2010tolerated option for treating acute non\u2010psychotic depression across a variety of bipolar disorder subtypes. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hup.1082","type":"journal-article","created":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T13:50:57Z","timestamp":1261489857000},"page":"30-36","source":"Crossref","is-referenced-by-count":11,"title":["Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8\u2010week open label trial"],"prefix":"10.1002","volume":"25","author":[{"given":"William V.","family":"Bobo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,12,22]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.11.1686"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0910"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200304000-00005"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.1.3"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2007.06.011"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0703"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.4088\/JCP.v65n1109","article-title":"Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community\u2010based sample","volume":"65","author":"Calabrese JR","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1351"},{"key":"e_1_2_1_10_1","unstructured":"Clinical Global Impressions.1976.ECDEU Assessment Manual for Psychopharmacology Revised (DHEW Publ No ADM 76\u2013338). National Institute of Mental Health: Rockville MD;218\u2013222."},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0514"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(97)00109-1"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.01.004"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.048504"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1399-5618.2003.00074.x"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.9.1537"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363190-00009"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200210000-00002"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1214"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.01210.x"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.6.530"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.3.261"},{"key":"e_1_2_1_23_1","first-page":"29","article-title":"International Consensus Group on Bipolar I Depression Treatment guidelines: synopsis and discussion","volume":"6","author":"Kramer TA","year":"2004","journal-title":"Med Gen Med"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01237.x"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620010-00003"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"issue":"1","key":"e_1_2_1_27_1","first-page":"1","article-title":"Second\u2010generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer JW","year":"2005","journal-title":"CNS Drugs"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.2001.00932.x"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064135"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0410"},{"key":"e_1_2_1_32_1","volume-title":"Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Patient Version","year":"1997"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200405000-00001"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0710"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181ad223f"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000248603.76231.b7"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e3181618eb4"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.7.1263"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.11.1079"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.4.337"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1281"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2008.11.003"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2006.02.011"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00219.x"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2003.00034.x"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.1082","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.1082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:30:02Z","timestamp":1700555402000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.1082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,22]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1002\/hup.1082"],"URL":"https:\/\/doi.org\/10.1002\/hup.1082","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,22]]}}}